Cwm LLC Trims Holdings in Thermo Fisher Scientific Inc. $TMO

Cwm LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,379 shares of the medical research company’s stock after selling 346 shares during the period. Cwm LLC’s holdings in Thermo Fisher Scientific were worth $4,614,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC lifted its holdings in shares of Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after acquiring an additional 33 shares during the period. Anderson Financial Strategies LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter worth about $30,000. Keystone Global Partners LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter worth about $31,000. IMA Advisory Services Inc. purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter worth about $35,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter worth about $37,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 400 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Up 1.7%

Shares of NYSE:TMO opened at $536.75 on Friday. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The company has a 50 day moving average of $494.18 and a two-hundred day moving average of $449.02. The company has a market capitalization of $202.68 billion, a price-to-earnings ratio of 31.04, a price-to-earnings-growth ratio of 2.87 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter last year, the company earned $5.37 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

TMO has been the topic of several recent analyst reports. Evercore ISI increased their price objective on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, October 8th. Wall Street Zen lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Sunday, October 12th. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a report on Tuesday, September 2nd. Finally, Hsbc Global Res lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $589.10.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.